Lung deposition of inhaled tobramycin with eFlow rapid/LC Plus jet nebuliser in healthy and cystic fibrosis subjects

J Cyst Fibros. 2011 Jan;10(1):9-14. doi: 10.1016/j.jcf.2010.08.019.


Background: Reducing nebulisation times for tobramycin solution for inhalation in cystic fibrosis (CF) may improve compliance.

Methods: In this single-dose, open-label, two-way crossover study, 13 subjects (7 CF, 6 healthy) were randomised to receive tobramycin via eFlow rapid or LC Plus jet nebuliser. Drug deposition in the lung using gamma scintigraphic imaging, nebulisation times, pharmacokinetics, and safety were evaluated.

Results: In CF patients, whole-lung deposition was 40% less with the eFlow rapid compared with LC Plus nebulisers was (8.9±0.8%, and 15.1±6.0%, p>0.05). Nebulisation time was shorter with eFlow rapid compared to LC Plus (7.0min versus 20.0min, p<0.05). Lung deposition in healthy subjects was comparable between both devices.

Conclusions: eFlow rapid reduces the nebulisation time of tobramycin and can potentially improved compliance in patients with CF.

Publication types

  • Clinical Trial, Phase I
  • Multicenter Study
  • Randomized Controlled Trial
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Administration, Inhalation
  • Adolescent
  • Adult
  • Aged
  • Anti-Bacterial Agents / administration & dosage
  • Anti-Bacterial Agents / adverse effects
  • Anti-Bacterial Agents / pharmacokinetics
  • Biological Availability
  • Cystic Fibrosis / diagnostic imaging
  • Cystic Fibrosis / drug therapy*
  • Cystic Fibrosis / physiopathology
  • Dose-Response Relationship, Drug
  • Drug Delivery Systems
  • Drug Monitoring
  • Female
  • Humans
  • Lung / diagnostic imaging*
  • Male
  • Middle Aged
  • Nebulizers and Vaporizers*
  • Organ Specificity / drug effects
  • Radionuclide Imaging
  • Respiratory Function Tests
  • Tobramycin* / administration & dosage
  • Tobramycin* / adverse effects
  • Tobramycin* / pharmacokinetics


  • Anti-Bacterial Agents
  • Tobramycin